Interleukin 17RC (IL-17RC)
Overview
The IL-17 family of cytokines generally mediates inflammatory effects and has six members, IL-17A through F. Expression of IL-17A and IL-17F, the most closely related molecules in this family, is up-regulated in joints of rheumatoid arthritis patients, inflamed lung tissue, brains and spinal cords of multiple sclerosis patients and inflammatory bowel disease.
Typical of the company’s groundbreaking research, ZymoGenetics identified IL-17RC as the receptor for IL-17F and discovered that human IL-17RC also binds IL-17A with high affinity. A soluble version of IL-17RC has been shown to neutralize pro-inflammatory properties of IL-17A and IL-17F in vitro and therefore may have beneficial therapeutic effects in patients suffering from autoimmune diseases.
IL-17RC is being developed by ZymoGenetics and Merck Serono as a potential treatment for inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis.
|
Back
to top
